UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 10, 2012

 

 

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   0-19731   94-3047598

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

94404

(Zip Code)

(650) 574-3000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT

 

Item 5.07 Submission of Matters to a Vote of Security Holders

The 2012 Annual Meeting of Stockholders (the Annual Meeting) of Gilead Sciences, Inc. (Gilead) was held on May 10, 2012 in Millbrae, California. Of the 758,070,530 shares of Gilead’s common stock entitled to vote at the meeting, 641,235,008 shares were represented at the meeting in person or by proxy, constituting a quorum. The voting results are presented below.

Gilead’s stockholders elected 12 directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal. The votes regarding the election of directors were as follows:

 

Name

   Shares Voted For      Votes Withheld      Broker
Non-Votes
 

John F. Cogan

     583,050,660         10,925,430         47,258,918   

Etienne F. Davignon

     570,070,144         23,905,946         47,258,918   

James M. Denny

     573,379,503         20,596,587         47,258,918   

Carla A. Hills

     575,777,405         18,198,685         47,258,918   

Kevin E. Lofton

     576,896,650         17,079,440         47,258,918   

John W. Madigan

     576,143,743         17,832,347         47,258,918   

John C. Martin

     571,421,131         22,554,959         47,258,918   

Gordon E. Moore

     573,391,665         20,584,425         47,258,918   

Nicholas G. Moore

     576,858,891         17,117,199         47,258,918   

Richard J. Whitley

     576,657,236         17,318,854         47,258,918   

Gayle E. Wilson

     573,955,676         20,020,414         47,258,918   

Per Wold-Olsen

     580,646,228         13,329,862         47,258,918   

Gilead’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of Gilead’s Board of Directors as its independent registered public accounting firm for the fiscal year ending December 31, 2012. The proposal received the following votes:

 

Votes For

     633,893,092   

Votes Against

     6,727,036   

Abstentions

     614,880   

Broker Non-Votes

     0   

Gilead’s stockholders approved the advisory resolution approving the compensation of Gilead’s named executive officers as presented in its 2012 proxy statement related to the Annual Meeting. The proposal received the following votes:

 

Votes For

     449,357,944   

Votes Against

     140,507,801   

Abstentions

     4,110,345   

Broker Non-Votes

     47,258,918   


Gilead’s stockholders approved the stockholder proposal requesting that Gilead’s Board of Directors take steps to permit stockholder action by written consent. The proposal received the following votes:

 

Votes For

     310,027,587   

Votes Against

     280,794,565   

Abstentions

     3,153,938   

Broker Non-Votes

     47,258,918   

Gilead’s stockholders approved the stockholder proposal requesting that Gilead’s Board of Directors take steps to redeem Gilead’s poison pill unless the plan is subject to a stockholder vote. The proposal received the following votes:

 

Votes For

     469,884,886   

Votes Against

     121,929,847   

Abstentions

     2,161,357   

Broker Non-Votes

     47,258,918   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

GILEAD SCIENCES, INC.
(Registrant)

 

/s/ Robin L. Washington

Robin L. Washington

Senior Vice President and Chief Financial Officer

Date: May 14, 2012